These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4608340)

  • 61. [Trial of a new antivertigo drug: R306].
    Mounier-Kuhn P; Haguenauer JP; Bouchayer M; Bernard P
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac (1967); 1969 Mar; 18(3):195-6. PubMed ID: 4245687
    [No Abstract]   [Full Text] [Related]  

  • 62. [Stabilographic evaluation of anticholinergic and dopaminergic medication in parkinsonism].
    Cernacek J; Brezny I; Jagr J
    Rev Neurol (Paris); 1972 Aug; 127(2):302-3. PubMed ID: 4666635
    [No Abstract]   [Full Text] [Related]  

  • 63. [Combination of L-dopa and sulpiride in the treatment of Parkinson's disease].
    Brion S; Guérin R
    Cah Med; 1973 Jul; 14(8):695-8. PubMed ID: 4602472
    [No Abstract]   [Full Text] [Related]  

  • 64. [Treatment of the parkinsonian syndrome with L-dopa and amantadine].
    Pendefunda GH; Pollingher B; Stefanache F; Gavril A; Oprişan C; Merling M; Nemţeanu E; Ciuntu M; Koropitzer I
    Neurol Psihiatr Neurochir; 1973; 18(6):559-68. PubMed ID: 4790488
    [No Abstract]   [Full Text] [Related]  

  • 65. [L-dopa in the treatment of the Parkinsonian syndrome].
    Apostol-Pruskauer B; Voiculescu V
    Neurol Psihiatr Neurochir; 1973; 18(6):539-49. PubMed ID: 4790486
    [No Abstract]   [Full Text] [Related]  

  • 66. [Treatment of Parkinson's syndrome using L-dopa. 2].
    Glabb J; Hübner W; Glabb S
    Z Arztl Fortbild (Jena); 1973 Aug; 67(15):745-53. PubMed ID: 4594383
    [No Abstract]   [Full Text] [Related]  

  • 67. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
    Nygaard TG
    Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
    [No Abstract]   [Full Text] [Related]  

  • 68. [Type II Charcot-Marie-Tooth and dopa-sensitive Parkinson disease].
    Tranchant C; Ruh D; Warter JM
    Rev Neurol (Paris); 1994; 150(1):72-4. PubMed ID: 7801046
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
    Fischer PA
    Nervenarzt; 1974 Dec; 45(12):617-27. PubMed ID: 4614096
    [No Abstract]   [Full Text] [Related]  

  • 70. Parkinsonism and dystonia, pseudo-parkinsonism and pseudodystonia.
    Quinn NP
    Adv Neurol; 1993; 60():540-3. PubMed ID: 8420187
    [No Abstract]   [Full Text] [Related]  

  • 71. Stabilographic evaluation of dopaminergic and anticholinergic treatment of parkinsonism.
    Cernacek J; Brezny I; Jagr J
    Agressologie; 1973; 14(Spec No D):83-7. PubMed ID: 4608340
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.